Cure Breast Cancer Foundation Launches “Think Pink” Text-to-Donate Campaign for Mother’s Day 2018

Mother's Day Text to DonateThe Cure Breast Cancer Foundation (CBCF) is providing yet another easy way to Think Pink this Mother’s Day with the launch of a text-to-donate campaign that will raise important funds and advance innovative research that could dramatically change the treatment for breast cancer in the years to come.

Starting on Wednesday, May 9th, 2018, CBCF will accept mobile donations in a “Text for a Cure” initiative throughout Mother’s Day weekend.  To participate in the campaign and donate via phone, simply text the code: DONATE to (973) 828-0883 and follow the link to indicate the amount you’d like to contribute to the Clifton, N.J.-based not-for-profit 501(c) 3 charity.

All monies raised during the weekend will support trailblazing breast cancer research being conducted under the direction of noted oncologist, Dr. Larry Norton, at the world-renowned Memorial Sloan-Kettering Cancer Center and other national and international research facilities.   Since its inception in December 2007, CBCF has raised over $7 million for breast cancer research, which has been devoted entirely to Dr. Larry Norton’s and his colleagues’ research on the growth and spreading of breast cancer cells known as the Self-Seeding Theory. This research focuses on improving the understanding of not only breast cancer, but also other cancers.

Donors can also visit www.501auctions.com/cbcf to dedicate fund to support CBCF efforts.

For more information on the CBCF, please call (973) 471-CBCF (2223) or visit http://curebreastcancerfoundation.org.

Cure Breast Cancer Foundation

The Cure Breast Cancer Foundation (CBCF) is a Clifton, N.J. – based not-for-profit 501(c) 3 charity devoted to fund research on the growth and spreading of breast cancer cells, also known as the Self-Seeding Theory, at the Memorial Sloan-Kettering Cancer Center in Manhattan and other national and international cancer research facilities under the direction of Dr. Larry Norton, who serves as the Foundation’s Scientific Advisor.  The founder and president is Carly Abramson.  Her father, Andrew Abramson, is Treasurer.  For more information, call (973) 471-CBCF (2223), e-mail info@curebreastcancerfoundation.org or visit www.curebreastcancerfoundation.org.

Advertisements

CURE BREAST CANCER FOUNDATION PREPARES TO HOST TWO FUN-FILLED FUNDRAISING EVENTS IN MAY AND JUNE

Clifton, NJ – Cure Breast Cancer Foundation (CBCF) is preparing for two exciting fundraising events in the weeks ahead.

cure-breast-cancer-foundation-logo

Up first will be a special fitness class with Jena Karp, one of the most popular Flywheel instructors and a breast cancer survivor herself. Ms. Karp will host a special 45-minute indoor cycling experience to raise important funds and awareness for the Clifton, N.J.-based non-profit 501 (c) 3 organization.

IMG_2768

 

“Save The Tatas With Jena” will take place on Sunday, May 15th at Flywheel Sports-Tribeca located at 415 Greenwich Street, NY, NY. 100% of the proceeds from the event will be donated to Cure Breast Cancer Foundation (CBCF), which solely supports breast cancer research efforts under the direction of Dr. Larry Norton, the Deputy Physician-in-Chief for Breast Cancer Programs and the Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan-Kettering Cancer Center.

The initial 1 p.m. session has been completely reserved. Limited seats are still available for the 2 p.m. session with class fees starting from $40. For more information and to register for “Save The Tatas With Jena”, visit WWW.SAVETHETATASWITHJENA.SPLASHTHAT.COM.

Continue reading

Cure Breast Cancer Foundation Hosts First Annual The Gala Pink to Benefit Breast Cancer Research

This slideshow requires JavaScript.

One of the most anticipated events in the history of the Cure Breast Cancer Foundation (CBCF)  recently took place when the non-profit 501 (c) 3 organization hosts its first annual “The Gala Pink” at Three Sixty °, the spectacular rooftop venue with incredible views of New York City in Tribeca.

The first large-scale event ever to be hosted by CBCF’s Junior Board, The Gala Pink drew hundreds of supporters, donors and partners of the organization together to celebrate and recognize the year-long fundraising efforts of CBCF with cocktails, a dinner reception and special guest speakers highlighted by Dr. Elizabeth Comen, a noted medical oncologist at Memorial Sloan-Kettering Cancer Center.

The formal evening is a continuation of CBCF’s tireless work to raise funds for the self-seeding theory of breast cancer research of Dr. Norton, the Deputy Physician-in-Chief for Breast Cancer Programs and the Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan-Kettering Cancer Center, and other national and international research facilities. 100% of the proceeds from the event will be donated to the work of Dr. Norton and his colleagues.

The Gala Pink also featured a live and silent auction with enticing items.

“The key to our success has been the diligence and dedication of our board and committee members and the many donors, volunteers, corporate partners and more who are the foundation of all the events we host throughout the year, from our annual Golf Classic and walk-a-thons to fashion shows and shop for a cure specials,” says Andrew Abramson, Treasurer and Co-Founder of the Clifton, N.J.-based CBCF.

 

“The Gala Pink is the culmination of all their work and recognition of their commitment to this ground breaking breast cancer research. What better way to celebrate their efforts than with a fun night of drinks, food, mingling and the opportunity to bid for a cure.”

Breast cancer is one of the leading causes of cancer death among women. Most cases of primary disease (in the breast and the lymph nodes under the arm) are cured by modern therapy. But should the cells spread to other parts of the body the disease can be controlled, but rarely cured. Dr. Norton’s team is dedicated to changing this by focusing our efforts on a revolutionary new concept of cancer that offers many possibilities for new methods of diagnosis, treatment, and even prevention.

CBCF supports a dedicated team of physicians and scientists at Memorial Sloan Kettering Cancer Center in New York and New Jersey and their national and international collaborators.

All this work is coordinated by Dr. Norton, CBCF’s scientific advisor. It is based on the discovery that abnormal cell division is only one of the dangerous characteristic of cancer.

Cancer cells also have the capability of moving from one part of the body to another and indeed can circulate back to the place they came from in the first place—called “self‐seeding”—and become more aggressive in the process. When cancers are in one place—say the breast area—they can be removed completely or killed by irradiation; but the movement of cells is a bigger problem, one which Dr. Norton and his associates are tackling head on by using the most advanced weapons of medical science, including:

•             Studying the ability of a very particular kind of white blood cell—cytotoxic neutrophils—to kill cancer cells. These neutrophils and the molecules that stimulate them, called chemokines, are present in the blood of women with breast cancer but not in women without cancer. How these cells are stimulated and how their presence contributes to a good prognosis is the basis for ongoing work.

•             Studying the molecular make‐up of white blood cells (lymphocyte) that invade breast cancers and cancers of many other organs and can actually stimulate their growth. This discovery will likely enable not only diagnostic tools, but also open entirely new avenues of cancer therapy.

•             Studying how cancers evolve in their primary site (the breast) and in metastatic sites. By tracking the changes in DNA in individual cancer cells from several sites simultaneously in individual patients, CBCF scientists plan to monitor such movement as well as define the molecular mechanisms that make the cancer cancerous. This will open up many opportunities in diagnosis, prognostication (predicting the course of disease), and eventually therapy too.

•             Developing a mathematical understanding of breast cancer metastasis. With great effort to protect the confidentiality of the patients, CBCF scientists are examining these data to map patterns of spread. Results so far confirm the seeding concepts in that the patterns elucidated cannot be explained without incorporating self‐seeding.

•             Assessing the relationship between certain molecules derived from cancer cells found in blood—called miRNAs and exosomes—and the geometry of cancerous masses as measured on microscope slides and radiographic images. Cancer seeding has a direct influence on geometry, since more seeding produces more disorganized and denser masses. The goal here is to be able to interpret blood tests along with mammograms and MRIs to better predict who has cancer and who requires therapy.

•             Studying in New York and Israel the relationship between bone metabolism and breast cancer, finding intriguing relationships between the function of bone‐forming cells and breast cancer biology. This work relates to both breast cancer and osteoporosis, two common problems in post‐menopausal women throughout the world.

For more information on the CBCF, please call (973) 471-CBCF (2223) or visit http://www.curebreastcancerfoundation.org.

Cure Breast Cancer Foundation

The Cure Breast Cancer Foundation (CBCF) is a Clifton, N.J. – based not-for-profit 501(c) 3 charity devoted to fund research on the growth and spreading of breast cancer cells, also known as the Self-Seeding Theory, at the Memorial Sloan-Kettering Cancer Center in Manhattan and other national and international cancer research facilities under the direction of Dr. Larry Norton, who serves as the Foundation’s Scientific Advisor.  The founder and president is Carly Abramson.  Her father, Andrew Abramson, is Treasurer.  For more information, call (973) 471-CBCF (2223), e-mail info@curebreastcancerfoundation.org or visit http://www.curebreastcancerfoundation.org.

Memorial Sloan-Kettering Cancer Center Recognizes Work of Andrew Abramson, Co- Founder of Cure Breast Cancer Foundation

ANDREW ABRAMSON

ANDREW ABRAMSON

The tireless efforts of Cure Breast Cancer Foundation (CBCF), to raise important funds for breast cancer research have not gone unnoticed. The Memorial Sloan-Kettering Cancer Center recently bestowed a significant honor to the 501(c) 3 charity to recognize its work and the determination of its leaders.

The world-renowned cancer research and treatment institute acknowledged Andy and Lisa Abramson, co-founders of CBCF, listing their names as a Principal Benefactor of Memorial Sloan-Kettering engraved in the lobby of the Rockefeller Research Laboratories. Also recognized with an engraving was the charity itself, Cure Breast Cancer Foundation, Inc.

Under the direction of Mr. Abramson, and his daughter and co-founder Carly, the Clifton, N.J.-based CBCF has raised over $4.5 million since its inception in 2007. The money donated supports the research of Dr. Norton, Deputy Physician-in-Chief for Breast Cancer Programs and the Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan-Kettering Cancer Center.

CBCF’s efforts assist the research of Dr. Larry Norton, who is leading the fight against breast cancer with groundbreaking work that addresses cases when the disease spreads to other parts of the body where it can currently be controlled, but rarely cured. Dr. Norton’s team is dedicated to changing this by focusing our efforts on a revolutionary new concept of cancer that offers many possibilities for new methods of diagnosis, treatment, and even prevention.

CBCF supports a dedicated team of physicians and scientists at Memorial Sloan Kettering Cancer Center in New York and New Jersey and their national and international collaborators.

All this work is coordinated by Dr. Norton, CBCF’s scientific advisor. It is based on the discovery that abnormal cell division is only one of the dangerous characteristic of cancer.